Document:

EX-10.9

 Exhibit 10.9 

CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED
FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT 

MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE REGISTRANT 
 IF PUBLICLY
DISCLOSED, AND HAS BEEN MARKED WITH 

“[***]” TO INDICATE WHERE OMISSIONS HAVE
BEEN MADE. 
 NON-EXCLUSIVE LICENSE AGREEMENT 

THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made as of October 15, 2020 (the “Effective Date”)

 BETWEEN 
 PROVINCIAL HEALTH
SERVICES AUTHORITY, continued under the Societies Act of British Columbia and having its administrative offices at 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z
4E6 (“PHSA”); 
 AND 

TSCAN THERAPEUTICS, INC., a corporation incorporated under the laws of the state of [Delaware] and having its head office at 830 Winter
Street, Waltham, Massachusetts, U.S.A., 02451 
 (“TScan”) 

PHSA and TScan may be referred to individually as a “Party” and collectively as the “Parties”. 

WHEREAS 
  

	A.	 PHSA (through its division, the BC Cancer (“BC Cancer”)) holds the rights to certain Licensed
Patents (as defined herein) which is based on research undertaken by investigators at BC Cancer, the University of British Columbia (“UBC”) and Simon Fraser University (“SFU”). 

 

	B.	 PHSA is desirous of entering into this Agreement to grant a
non-exclusive license to TScan to exploit the Licensed Patents for the public benefit and in a manner consistent with PHSA’s status as a non-profit, tax exempt
institution, and TScan is desirous of accepting such license, on the terms and conditions set out in this Agreement. 

 NOW
THEREFORE in consideration of the promises and the performance of the covenants herein contained and other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Parties agree as follows: 

 ARTICLE 1 

DEFINITIONS 
  

	1.1	 Definitions. For the purposes of this Agreement, the following terms will have the following meanings:

  

	 	(a)	 “Affiliate” means, with respect to a Person, any other Person (other than an individual) that,
directly or indirectly, whether as of or after the Effective Date, through one (1) or more intermediaries, controls, is controlled by or is under common control with such first Person at any time for so long as such Person controls, is
controlled by or is under common control with such first Person. For purposes of this Agreement, “control” and, with correlative meanings, the terms “controlled by” and “under common control with”
means: the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or
the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling
entity). 

  

	 	(b)	 “Agreement Payments” has the meaning given to it in Section 4.4(c).

  

	 	(c)	 “Anti-Corruption Laws” means the federal laws of Canada and the laws of the Province of
British Columbia relating to anti-bribery or anti-corruption matters, together with the United States Foreign Corrupt Practices Act, and any other applicable anti-bribery or anti-corruption laws. 

 

	 	(d)	 “Applicable Laws” means all applicable laws, rules, and regulations, including any rules,
regulations, guidelines, or other requirements of Governmental Authorities, that may be in effect from time to time. 

  

	 	(e)	 “BC Cancer” has the meaning given to it in the recitals. 

 

	 	(f)	 “BIA” has the meaning given to it in Section 10.6. 

 

	 	(g)	 “Business Day” means any day, other than a Saturday or a Sunday, on which banking institutions
are open or authorized to be open in Vancouver, Canada or Boston, Massachusetts. 

  

	 	(h)	 “Calendar Year” means each successive period of twelve (12) months commencing on
January 1 and ending on December 31, except that the first Calendar Year of the Term will commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term will
commence on January 1 of the year in which the Term ends and end on the last day of the Term. 

  

	 	(i)	 “CCAA” has the meaning given to it in Section 10.6. 

 

	 	(j)	 “Claim” means any cause of action, action, account, lien of any kind whatsoever, claim,
demand, complaints, grievances, applications, suits, causes of action, lawsuits, audit, proceeding, or arbitration, including any proceeding or investigation by a Governmental Authority. 

 

	 	(k)	 “Clinical Trials” means human studies designed to measure the safety or efficacy of a Product,
and any post-marketing approval studies. 

  
 - 2 - 

	 	(l)	 “Confidential Information” means any information which is confidential in nature or that is
treated as being confidential by a Party or by any of its Affiliates and that is furnished or transferred by or on behalf of such a Party or any of its Affiliates (collectively, the “Disclosing Party”) to the other Party or to any
of its Affiliates (collectively, the “Receiving Party”) pursuant to this Agreement. If such information is not furnished or transferred in writing by the Disclosing Party to the Receiving Party then, unless the Receiving Party knows
or reasonably should know such information is confidential, it will not be considered Confidential Information unless reduced to writing and provided by the Disclosing Party to the Receiving Party within [***] days of the original disclosure.

  

	 	(m)	 “Disclosing Party” has the meaning given to it in Section 1.1(l). 

 

	 	(n)	 “Dispute” means any dispute, controversy or Claim between the Parties (of any and every kind
or type, whether based on contract, tort, statute, regulation or otherwise) arising out of, relating to or connected with this Agreement or the activities carried out under this Agreement, including any dispute as to the construction, validity,
interpretation, enforceability or breach of this Agreement. 

  

	 	(o)	 “Encumbrances” means pledges, liens, charges, security interests, leases, title retention
agreements, mortgages, restrictions, options or adverse Claims or encumbrances of any kind or character whatsoever. When used as a verb, “to Encumber” mean to grant or permit an Encumbrance. 

 

	 	(p)	 “Force Majeure” has the meaning given to it in Section 13.10. 

 

	 	(q)	 “Governmental Authority” means any court, agency, authority, department, regulatory body or
other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member.

  

	 	(r)	 “Indemnitees” has the meaning given to it in Section 9.1. 

 

	 	(s)	 “Intellectual Property” means all intellectual property as recognized under the Applicable
Laws of Canada, the United States or other jurisdictions as applicable, including rights in and to Patents. 

  

	 	(t)	 “Licensed Patents” means: (a) the patents or patent applications
(“Patents”) set out in Schedule A; (b) any and all Patents claiming priority to or corresponding to any of the Patents set out in Schedule A or to which the Patents set out in Schedule A claim priority or otherwise claim the
subject matter of the Patents set out in Schedule A (and their international equivalents); (c) any divisionals, continuations, continuations-in-part (to the extent
claiming the subject matter of the Patents set out in Schedule A), and continued prosecution applications of the Patents described in clause (a) or (b) (and their international equivalents); (d) any Patents resulting from any of the Patents
described in clause (a), (b) or (c) (and their international equivalents); and (e) any Patents resulting from reissues, reexaminations or extensions (and their international equivalents) of any Patents described in clause (a), (b), (c), or (d).

  

	 	(u)	 “Party Claiming Force Majeure” has the meaning given to it in Section 13.10.

  
 - 3 - 

	 	(v)	 “Patent Challenge” has the meaning given to it in Section 7.2. 

 

	 	(w)	 “Patent Prosecution” means activities directed to: (i) preparing, filing and prosecuting
applications (of all types) for any Licensed Patents; (ii) managing any interference, opposition, re-issue, reexamination, supplemental examination, invalidation proceedings (including
inter partes or post-grant review proceedings), revocation, nullification, or cancellation proceeding relating to the foregoing; (iii) maintaining any Licensed Patents; (iv) deciding whether to abandon, extend or
maintain Licensed Patents; (v) listing in regulatory publications (as applicable); and (vi) settling any interference, opposition, reexamination, invalidation, revocation, nullification or cancellation proceeding, but excluding the defense
of challenges to such Licensed Patent or Licensed Patent application as a counterclaim in an infringement proceeding with respect to the particular Licensed Patent and the prosecution of infringement proceedings with respect to a particular Licensed
Patent, and any appeals therefrom. 

  

	 	(x)	 “Person” means any natural person, corporation, limited liability corporation, unincorporated
association, partnership, joint venture or other entity. 

  

	 	(y)	 “Public Official” means (i) any officer, employee or representative of any regional,
federal, state, provincial, county or municipal government or government department, agency or other division; (ii) any officer, employee or representative of any commercial enterprise that is owned or controlled by a government, including any
state-owned or controlled veterinary, laboratory or medical facility; (iii) any officer, employee or representative of any public international organization, such as the African Union, the International Monetary Fund, the World Health
Organization, the United Nations or the World Bank; and (iv) any person acting in an official capacity for any government or government entity, enterprise or organization identified above. 

 

	 	(z)	 “Receiving Party” has the meaning given to it in Section 1.1(l). 

 

	 	(aa)	 “Securities Regulators” has the meaning given to it in Section Error! Reference source not
found.. 

  

	 	(bb)	 “SFU” has the meaning given to it in the recitals. 

 

	 	(cc)	 “Sublicense Agreement” means any agreement under which TScan, a TScan Controlled Subsidiary,
or a Sublicensee grants a sublicense licenses under the Licensed Patents to a Sublicensee. 

  

	 	(dd)	 “Sublicensee” means any Third Party or TScan Affiliate (other than a TScan Controlled
Subsidiary) who has obtained, directly or indirectly, from or through TScan, Tscan Controlled Subsidiary, or a Sublicensee a sublicense of any or all of the Licensed Patents granted under this Agreement to TScan. A Sublicensee and all of its
Affiliates shall be considered a single Sublicensee for all purposes of this Agreement. 

  

	 	(ee)	 “Sublicensee Entity” has the meaning given in Schedule “B”. 

  
 - 4 - 

	 	(ff)	 “Taxes” means any federal, state, local or foreign income, gross receipts, license, payroll,
employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, sales, use,
transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.

  

	 	(gg)	 “Term” has the meaning given to it in Section 10.1. 

 

	 	(hh)	 “Territory” means worldwide. 

 

	 	(ii)	 “Third Party” means a Person other than PHSA or its Affiliate or TScan or a TScan Controlled
Subsidiary. 

  

	 	(jj)	 “Third Party Claim” means a Claim brought against a Party by a Third Party.

  

	 	(kk)	 “Trademarks” means trademarks, service marks, certification marks, official marks, trade
names, trade dress, distinguishing guises and other distinguishing features used in association with wares or services, logos, slogans, business names, corporate names, uniform resource locators, trading styles, commercial symbols and other source
and business identifiers, designs, domain names, whether registered primary domain names or secondary or other higher level domain names, and general intangibles of like nature, whether or not registered or the subject of an application for
registration and whether or not registrable and all goodwill associated therewith. 

  

	 	(ll)	 “TScan Controlled Subsidiary” means an entity in which TScan owns 50% or more of the voting
shares of such entity and has the right to elect the majority of the board of directors (or equivalent in respect of jurisdictions or entities that do not have a board of directors) of such entity. 

 

	 	(mm)	 “TScan Technology License” means a license of (i) material Patents other than the
Licensed Patents, or (ii) material Know-How, in each case, owned or exclusively licensed by TScan and granted under the Sublicense Agreement in connection with a sublicense of any or all of the Licensed
Patents in which the scope and term of the sublicense to Licensed Patents is no broader than the scope of the license or sublicense, as the case may be, granted to such other Patents or Know-How owned or
exclusively licensed by TScan. 

  

	 	(nn)	 “UBC” has the meaning given to it in the recitals. 

ARTICLE 2 

LICENSES 
  

	2.1	 Grant of License. Effective upon receipt by PHSA of the amounts payable pursuant to Section 4.1,
PHSA hereby grants to TScan on the Effective Date a worldwide, non-exclusive, perpetual, non-transferable (except as set forth herein) license, with right to grant sublicenses through multiple tiers (but, for
clarity, the Sublicense of the Licensed Patents and the TScan Technology License shall be included in the same agreement with the Sublicensee or sub-Sublicensee), under the Licensed Patents, to make, have
made, use, offer for sale, import, and sell products and services and otherwise practice under the Licensed Patents in any way. 

  
 - 5 - 

	2.2	 TScan Controlled Subsidiaries; Affiliates. The license granted under Section 2.1 shall extend to
any TScan Controlled Subsidiary (but not to any other Affiliate of TScan that is not a TScan Controlled Subsidiary) but shall terminate on the date such entity ceases to be a TScan Controlled Subsidiary. A list of all TScan Controlled Subsidiaries
as of the Effective Date is attached as Schedule C. Upon request from time-to-time from PHSA, TScan shall notify PHSA in writing of its then current TScan Controlled
Subsidiaries. TScan will cause each TScan Controlled Subsidiary to comply with the terms and conditions of this Agreement applicable to it and will be fully responsible for the compliance of each TScan Controlled Subsidiary with the terms and
conditions of this Agreement. TScan may grant a sublicense to an Affiliate that is not a TScan Controlled Subsidiary but, in such case, such entity shall be deemed a Sublicensee and such sublicense shall be subject to payment pursuant to
Section 4.2 and the terms set out in Section 2.3. 

  

	2.3	 Sublicensing to Third Parties. In addition to its rights pursuant to Section 2.2, TScan,
TScan Controlled Subsidiaries, and Sublicensees may grant one or more sublicenses of the licenses granted to TScan under the Licensed Patents pursuant to Section 2.1 without the consent of PHSA but only pursuant to a TScan Technology License.
TScan will pay the Sublicensing Fee (as defined in Section 4.2 and only to the extent required by Section 4.2) with respect to such sublicense irrespective of whether such sublicense is granted by TScan, a TScan Controlled Subsidiary or a
Sublicensee. TScan agrees (and, with respect to Sublicensees and TScan Controlled Subsidiaries that grant sublicenses, shall cause such Persons to agree) to the following with respect to each Sublicense Agreement it enters into:

  

	 	(a)	 will not conflict or be inconsistent in any material respect with the terms and conditions of this Agreement
and such Sublicense Agreement will be in writing and will contain the terms and conditions outlined in Schedule B; 

  

	 	(b)	 TScan shall provide PHSA with the information set out in Schedule D in respect of each Sublicense Agreement and
Sublicensee (whether such Sublicense Agreement is entered into by TScan, any TScan Controlled Subsidiary or Sublicensee) within [***] of the grant of any sublicense.. 

 

	2.4	 Sublicense Agreement. For clarity, neither TScan, any TScan Controlled Subsidiary nor any Sublicensee
will grant any sublicense of the Licensed Patents without first entering into a Sublicense Agreement. 

  
 - 6 - 

 ARTICLE 3 

DEVELOPMENT; COMMERCIALIZATION; REGULATORY 
  

	3.1	 Development/Commercialization/Regulatory Responsibilities. As between the parties, TScan, or its
Sublicensees will be fully responsible at its cost for the development and commercialization of any products or services that may be covered under the Licensed Patents in the Territory. PHSA shall not have any regulatory responsibilities in
connection with such development and commercialization by TScan, its TScan Controlled Subsidiaries and Sublicensees of such products or services. TScan will, and will cause its TScan Controlled Subsidiaries, to comply with all Applicable Laws in
connection with the exploitation of the Licensed Patents and the development and commercialization of any such products or services. 

ARTICLE 4 

FINANCIAL TERMS; PAYMENTS 
  

	4.1	 Up-Front Payment. Concurrent with the execution of this
Agreement, TScan will pay to PHSA a non-refundable: 

  

	 	(a)	 US $[***] as an up-front license fee; plus 

 

	 	(b)	 a one-time reimbursement of Patent and legal costs incurred to date by
PHSA related to the Licensed Patents, of US $[***]. 

  

	4.2	 Sublicensing Fee. In addition to the amounts payable under Sections 4.1 and 4.3, TScan shall pay (or
cause a Sublicensee to pay) to PHSA an up-front US$[***] sublicensing fee (the “Sublicensing Fee”) for each Sublicense Agreement; provided, however, that where such fee was paid by TScan to
PHSA in respect of a particular Sublicensee, such fee shall not be due with respect to any Sublicense Agreement between that Sublicensee and its Affiliates but, for clarity, additional Sublicensing Fees shall be payable by TScan to PHSA in respect
of any sub-sublicense by such Sublicensee or its Affiliate to any other Person. For further clarity, any Sublicense Agreement that grants a sublicense under the Licensed Patents to a Third Party and its
Affiliates shall be deemed one Sublicense Agreement, with no more than one (1) Sublicensing Fee payable with respect thereto (if any).    The Sublicense Fees will be payable to PHSA within [***] following the execution of a
Sublicense Agreement. For the purpose of calculating Sublicensing Fees owing by TScan to PHSA, each Affiliate of such Sublicensee shall be deemed to be the same Sublicensee and the grant of a sublicense in accordance with the terms of this Agreement
by such Sublicensee to its Affiliate shall not require payment by TScan to PHSA of an additional Sublicensing Fee (beyond that already paid to PHSA in connection with the grant of the sublicense by TScan to the applicable Sublicensee) for so long as
such entity remains an Affiliate of the original Sublicensee. If such Person is no longer an Affiliate of such Sublicensee and retains the sublicense to the Licensed Patents, then TScan shall be obligated to pay to PHSA an additional US$[***]
Sublicensing Fee in respect of such sublicense to such Person as if it were a new sublicense of the Licensed Patents granted by TScan to such Person unless such Person is an Affiliate of a Person for which a Sublicensing Fee has been (or is
concurrently) paid. The Sublicensing Fees will not be creditable against any other payments owing by TScan to PHSA under this Agreement and will not be refundable by PHSA if the Sublicense Agreement giving rise to such Sublicensing Fee.

  

	4.3	 Minimum Annual Fee for the First Five Years. In addition to the other amounts payable under this
Agreement, TScan will pay to PHSA an annual license maintenance fee of US$[***] per year for five years (for a total of US$[***]), with the first such payment commencing on the first anniversary of the Effective Date and the subsequent payments due
on each subsequent anniversary date thereafter until the fifth such payment has been made to PHSA. The amount payable under this Section 4.3 will not be creditable against any other payments owing by TScan to PHSA under this Agreement.

  
 - 7 - 

	4.4	 Payments; Reporting. 

 

	 	(a)	 Sublicensing Fee and Reporting. Concurrent with the payment of a Sublicensing Fee pursuant to
Section 4.2, TScan will deliver to PHSA a report containing the information specified in Schedule D to this Agreement. 

  

	 	(b)	 Payment Currency / Exchange Rate. All payments to be made by TScan to PHSA under this Agreement will be
made in United States dollars. Payments to PHSA will be made by electronic wire transfer of immediately available funds to an account of PHSA designated in writing by PHSA to TScan. 

 

	 	(c)	 Taxes. Each Party will be responsible for its own Tax liabilities arising under this Agreement, provided
that PHSA will be liable for all Taxes imposed upon any payments made by TScan to PHSA under this Agreement (“Agreement Payments”). If Applicable Laws require the withholding of Taxes, TScan will make such withholding payments and
will subtract the amount thereof from the Agreement Payments and submit to PHSA appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time. TScan will provide PHSA reasonable assistance in
order to allow PHSA to obtain the benefit of any present or future treaty against double taxation or refund or reduction in Taxes which may apply to the Agreement Payments. Notwithstanding the foregoing, if as a result of a Party assigning this
Agreement or changing its domicile additional Taxes become due that would not have otherwise been due hereunder with respect to Agreement Payments, such Party will be responsible for all such additional Taxes. The Parties will, where possible and,
in the case of PHSA, consistent with any policies or other requirements applicable to such PHSA, endeavor to reasonably cooperate in order to mitigate adverse tax consequences to a Party that may arise as a result of this Agreement, including by
completing, filing, or delivering documents to lawfully enable PHSA, and TScan, its Affiliates and Sublicensees, to mitigate withholding taxes applicable to any of them. 

 

	 	(d)	 Additional Payment Terms; Late Payment. All payments in this Article 4 are non-refundable and non-creditable and will be paid by TScan without notice or demand therefor. Late payments, unless disputed by TScan in good faith, will bear a rate of
[***]% compound interest per month (equivalent to [***]% per annum), or the maximum rate permitted by law, whichever is lower on the entire outstanding balance from the due date. 

 

	4.5	 Records; Audits. TScan will keep true and accurate books, records and accounts sufficient to permit PHSA
to determine TScan’s payment obligations under this Agreement in accordance with, and subject to, this Section 4.5. During the Term and for [***] years thereafter, at the request of PHSA, and not more than once per Calendar Year, TScan
will, within [***] Business Days of a written request by PHSA, permit an independent auditor from an internationally recognized accounting firm selected by PHSA and acceptable to TScan, acting reasonably, during ordinary business hours to have
access to TScan’s records in order to verify the accuracy of the Sublicensing Fees 

  
 - 8 - 

	 	
payable under this Agreement. As a condition of the foregoing, such auditor will be required to enter into with TScan a confidentiality agreement in a form mutually agreeable to PHSA and TScan,
each acting reasonably, that will require such auditor to keep all information confidential except that such auditor may share with PHSA only its conclusions of such audit and such information as is reasonably required to support such conclusions.
TScan will reasonably cooperate at TScan’s sole cost and expense in any review or inspection conducted under this Section and make reasonably available on a timely basis the information required to conduct the review or inspection. If the
review of such records reveals an underpayment by TScan, then TScan will promptly pay to PHSA the underpayment together with interest calculated in the manner provided in Section 4.4(d). The fees and expenses of such independent auditor will be
borne by PHSA, provided that if such audit reveals that TScan failed to pay Sublicensing Fees owed to PHSA by more than $[***] then the reasonable fees and expenses of PHSA’s auditor in performing such audit will be borne by TScan.

 ARTICLE 5 

OWNERSHIP OF INTELLECTUAL PROPERTY 
  

	5.1	 Licensed Patents. PHSA owns all right, title and interest in and to the Licensed Patents.

  

	5.2	 TScan Improvements. TScan shall not be required to assign to PHSA any improvements (or any other
intellectual property of any kind) created or developed by TScan, its Affiliates or Sublicensees. 

  

	5.3	 PHSA’ Retained Rights. Except for the licenses and rights under the Licensed Patents expressly set
forth in this Agreement, no license, immunity, interest, or other right is or shall be deemed to be granted or otherwise conveyed under or pursuant to this Agreement by PHSA under any other patents or technology, whether directly, by implication, by
reason of estoppel, or otherwise. Without limiting the generality of the foregoing, TScan acknowledges and agrees that: 

  

	 	(a)	 PHSA and and its Affiliates retain the right to use and exploit, including for both non-commercial and commercial purposes, the Licensed Patents in the Territory; and 

  

	 	(b)	 PHSA and its Affiliates may grant non-exclusive licenses to one or more
Third Parties in the Territory in respect of the Licensed Patents without any obligation to, accounting to or reporting to TScan. 

ARTICLE 6 

CONFIDENTIALITY 
  

	6.1	 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in
writing by the Parties, each Receiving Party agrees that, during the Term, and for [***]Calendar Years thereafter (or, in the case of any trade secrets, for so long as they remain secret), the Receiving Party will keep confidential and will not
publish or otherwise disclose and will not use for any purpose other than as expressly provided for in this Agreement any Confidential Information made available by the Disclosing Party

  
 - 9 - 

	 	
pursuant to this Agreement. The Receiving Party may use Confidential Information of the Disclosing Party only to the extent required to accomplish the purposes of this Agreement. The Receiving
Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of
the Confidential Information. The Receiving Party will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information. 

 

	6.2	 Exceptions. Confidential Information will not include any information which the Receiving Party can
prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available; (b) is known by the Receiving Party at the time of receiving such information
from the Disclosing Party, as evidenced by its records; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the
Receiving Party without the use of Confidential Information of the Disclosing Party. 

  

	6.3	 Authorized Disclosure. The Receiving Party may disclose Confidential Information of the Disclosing Party
if and to the extent such disclosure is reasonably necessary in the following instances: 

  

	 	(a)	 disclosure to Affiliates, to potential or actual licensees or sublicensees, and to employees, contractors,
consultants, agents or other representatives of the Receiving Party and its Affiliates who have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement provided, in each
case, that any such Affiliate, potential or actual sublicensee, or employee, contractor, consultant, agent or other representative agrees to be bound or are bound by confidentiality obligations comparable in scope to those set forth in this
Article 6; 

  

	 	(b)	 disclosure to such Receiving Party’s attorneys, independent accountants or financial advisors for the sole
purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the Receiving Party, on the condition that such attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with the confidentiality provisions of this Agreement as they apply to the Receiving Party; 

  

	 	(c)	 disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties
provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as stringent as set out in this Article 6; 

 

	 	(d)	 as approved by the Disclosing Party in writing for disclosure or publication by each of the Parties;

  

	 	(e)	 prosecuting or defending Claims as permitted by this Agreement; and 

  
 - 10 - 

	 	(f)	 complying with applicable court orders, Applicable Laws, rules or regulations, or the listing rules of any
exchange on which the Receiving Party’s securities are traded, provided that: in the event the Receiving Party is required to make a disclosure of the Confidential Information of the Disclosing Party pursuant to this Section 6.3(f), it
will, except where prohibited or impracticable, give reasonable advance notice to the Disclosing Party of such disclosure so that the Disclosing Party is afforded a reasonable opportunity to oppose such requirement or otherwise seek an appropriate
protective order. 

  

	6.4	 Confidentiality of Terms of Agreement. The terms of this Agreement will be considered the Confidential
Information of PHSA for purposes of this Article 6, provided that TScan may disclose the terms of this Agreement to Sublicensees and in connection with due diligence pursuant to a financing, acquisition or securities transaction if such
recipient agrees to maintain such information confidential on terms no less stringent than those set out in this Article 6. 

  

	6.5	 Additional PHSA Disclosures. Notwithstanding anything contained in this Article 6, TScan acknowledges
and agrees that: (i) PHSA may to disclose to UBC and SFU, and PHSA, UBC and SFU may each disclose to the inventors of the Licensed Patents, all financial reports or payment information provided by TScan pursuant to this Agreement; and
(ii) PHSA may disclose any other TScan Confidential Information received pursuant to this Agreement to UBC and SFU, provided in the case of this subsection (ii) that such recipient agrees to be bound by terms of confidentiality and
restrictions on use at least as stringent as those set forth in this Article 6. 

  

	6.6	 Freedom of Information Disclosures. The Parties acknowledge that PHSA, UBC and SFU may be required to
disclose records relating to this Agreement pursuant to the Freedom of Information and Protection of Privacy Act (“FIPPA”). PHSA, UBC and SFU will comply with all of the provisions of FIPPA relating to disclosure of records
before making any such disclosure pursuant to FIPPA, including the notice, review and appeal provisions with respect to third party requests for disclosure, but will not be liable in any way whatsoever to TScan or its employees, contractors, agents,
subcontractors, representatives, Affiliates, or Sublicensees, if such records (including the information therein) are required to be so disclosed pursuant to FIPPA, provided they otherwise comply with their obligations herein. Without limiting the
generality of the foregoing, PHSA will, and if they are not already bound to do so by FIPPA, will request that UBC and SFU agree to, provide TScan written notice in accordance with section 23 of FIPPA before disclosing any records relating to this
Agreement pursuant to FIPPA, and will limit the disclosure to the minimum amount which PHSA, UBC or SFU, as applicable, reasonably determines after consultation with TScan is required to be disclosed under FIPPA. 

 

	6.7	 Publication. Notwithstanding anything to the contrary in this Agreement, PHSA, UBC and SFU are not
restricted from presenting at symposia, national or regional professional meetings or from publishing in journals or other publications accounts of their respective research relating to the Licensed Patents. 

 

	6.8	 Use of Trademarks. Notwithstanding the licenses conferred under this Agreement, and except as may
otherwise be agreed to by the Parties, neither Party will use the other Party’s Trademarks, or the names of the other Party’s employees, in any advertising or sales promotional material, without prior written permission of that other
Party. Any Party granting such approval will comply with any and all restrictions on such use as a Party may provide in writing from time to time. Notwithstanding this Section 6.8, each Party may use the legal or trade name of the other Party
only where necessary to reflect the factual nature of a Party’s participation in, or activities under, this Agreement, and then only in a disclosure or publication as permitted by this Agreement. 

  
 - 11 - 

	6.9	 Press Releases. Each Party agrees not to issue any press release or other public statement, whether oral
or written, disclosing the terms or the names of the Parties of this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed), provided, however, that neither Party will be
prevented from complying with any duty of disclosure it may have pursuant to Applicable Laws or pursuant to the rules of any recognized stock exchange or quotation system, subject to (and to the extent there is sufficient time while still being able
to comply with such Applicable Laws or stock exchange or quotation system rules) that Party notifying the other Party of such duty and limiting such disclosure as reasonably requested by the other Party (and giving the other Party sufficient time to
review and comment on any proposed disclosure). Notwithstanding the foregoing, disclosures of information for which consent has previously been obtained under this Section will not require advance approval but will be provided to the other Party as
soon as practicable after the release or communication thereof. 

  

	6.10	 Securities Exchanges. The Parties hereby acknowledge and agree that TScan may be required by Applicable
Laws to submit a copy of this Agreement to a national or sub-national securities regulatory body in any jurisdiction (collectively, the “Securities Regulators”). If TScan is required by
Applicable Laws to submit a description of the terms of this Agreement to or file a copy of this Agreement with any Securities Regulator, then it will have the right to make such disclosure or filing at the time and in the manner reasonably
determined by its counsel to be required by Applicable Laws or the applicable Securities Regulators after consultation with PHSA on the proposed disclosure or filing and, to the extent not inconsistent with TScan’s obligations under Applicable
Laws or the rules of the applicable Securities Regulators, providing PHSA with reasonable time to comment upon and request confidential treatment for such disclosure. 

 

	6.11	 If TScan seeks to make a disclosure or filing as set forth in this Section 6.10 and PHSA provides comments
within the respective time periods or constraints specified herein, TScan will in good faith incorporate such comments unless it reasonably determines that it is not permitted to do so under Applicable Laws or the applicable Securities Regulators
and advises PHSA of such determination and the reasons therefor. 

  

	6.12	 Injunctive Relief for Breach. In the event of any breach of this Article 6 by a Party, the
aggrieved Party will be entitled to seek preliminary and permanent injunctive relief, which remedy will be in addition to any other rights or remedies the aggrieved Party may be entitled under this Agreement or otherwise under Applicable Laws.

 ARTICLE 7 

PATENT PROSECUTION; INFRINGEMENT 
  

	7.1	 Prosecution of Licensed Patents. PHSA will have the sole right to manage the Patent Prosecution of the
Licensed Patents and to enforce the Licensed Patents as PHSA, in its sole discretion, determines and without the consent of or accounting to TScan, including the right to elect whether or not to continue the prosecution or maintenance of, to abandon
or to enforce against Third Parties, any Licensed Patent in any country in the Territory. 

  
 - 12 - 

	7.2	 Patent Challenge. If TScan, its Affiliates, or any Third Party acting under the direction of Tscan or
its Affiliates: 

  

	 	(a)	 challenges the validity or of any Licensed Patent (or any claim thereof) under this Agreement by way of a
declaratory judgment action or any other legal proceedings, and if such challenger withdraws the suit or it ends in a final judgment from which no appeal can be or has been taken as a matter of right that any of the claims of any Licensed Patent is
valid or enforceable; 

  

	 	(b)	 initiates or participates in a re-examination, review or other
proceeding at the United States Patent and Trademark Office or any foreign equivalent with respect to any Licensed Patent, and if such governmental authority issues a review decision, reexamination certificate or similar document indicating that any
claim of any of the Licensed Patent is valid or institution is denied (without regard to whether any claim of any Licensed Patent is amended during re-examination or review); or 

 

	 	(c)	 otherwise disputes the validity of Licensed Patents, directly or indirectly through a representative, or any
rights or interests of PHSA in, to or under any of the Licensed Patents; 

 and the foregoing is not a defense against a
claim, action proceeding alleging infringement of the Licensed Patents by TScan, a TScan Controlled Subsidiary or any of their respective Affiliates asserted by PHSA against such Person (each of the actions referred to in (a), (b) and/or
(c) above), as qualified, when initiated or filed, is a “Patent Challenge”) then PHSA can terminate this Agreement upon [***] days notice to TScan. TScan shall give PHSA at least [***] prior written notice prior to TScan or its
Affiliates or any Third Party acting under any of their direction commencing a Patent Challenge.     
 ARTICLE 8

 REPRESENTATIONS AND WARRANTIES 
  

	8.1	 Representations and Warranties of the Parties. Each of the Parties represents and warrants to the other
that as of the Effective Date: 

  

	 	(a)	 it is duly organized, validly existing and in good standing under the Applicable Laws of the jurisdiction of
its incorporation and has full power and authority to enter into this Agreement and to carry out the provisions hereof; 

  

	 	(b)	 the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action and do not violate: (i) such Party’s charter documents, bylaws or other organizational documents; (ii) any requirement of any Applicable Laws; or (iii) any order, writ,
judgment, injunction, decree, determination or award of any court or Governmental Authority presently in effect applicable to such Party; 

  
 - 13 - 

	 	(c)	 this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with
its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general
principles of equity (whether enforceability is considered a proceeding at law or equity); and 

  

	 	(d)	 it has not in connection with the transactions contemplated by this Agreement: (i) taken any action in
violation of any applicable Anti-Corruption Laws; (ii) corruptly offered, paid, given, promised to pay or give, or authorized the payment or gift of anything of value, directly or indirectly, to any Public Official, for the purposes of:
(A) influencing any act or decision of any Public Official in his or her official capacity; (B) inducing such Public Official to do or omit to do any act in violation of his or her lawful duty; (C) securing any improper advantage; or
(D) inducing such Public Official to use his or her influence with a government, governmental entity, or commercial enterprise owned or controlled by any government (including state-owned or controlled veterinary, laboratory or medical
facilities) in obtaining or retaining any business whatsoever. 

  

	8.2	 Limited Representation and Warranties of PHSA. PHSA represents and warrants that it has not
granted exclusive rights, or assigned any rights of PHSA in, the Licensed Patents to Third Parties that would prevent PHSA from granting to TScan the non-exclusive licenses granted under the License Agreement.

  

	8.3	 Disclaimer. TScan acknowledges and agrees that, except as specifically set out in Section 8.2:

  

	 	(a)	 the Licensed Patents and the license granted thereto under this Agreement are provided “as is”;

  

	 	(b)	 PHSA expressly disclaims any warranty or condition that the use of the Licensed Patents does not infringe any
patent, copyright, Trademark, trade secret or other rights of Third Parties; 

  

	 	(c)	 PHSA makes no representation, warranty or condition with respect to the Licensed Patents;

  

	 	(d)	 TScan has been advised by PHSA to undertake TScan’s own due diligence regarding the Licensed Patents;

  

	 	(e)	 PHSA disclaims all representations, warranties or conditions with regard to the Licensed Patents, including,
but not limited to, all warranties or conditions, expressed or implied, of merchantability, merchantable quality, durability, and fitness for any particular purpose; and 

 

	 	(f)	 PHSA additionally disclaims all obligations and liabilities on the part of PHSA and its Affiliates, and
disclaims on behalf of UBC and SFU, for damages including, but not limited to, direct, indirect, special, and consequential damages, solicitors’ and experts’ fees, and court costs (even if they have been advised of the possibility of such
damages, fees or costs), arising out of or in connection with the use, research, development, or commercialization of the Licensed Patents by TScan, its Affiliates or any Sublicensees. 

  
 - 14 - 

 ARTICLE 9 

INDEMNITIES; LIMITATION OF LIABILITY; INSURANCE 
  

	9.1	 Indemnity. TScan hereby indemnifies, holds harmless and defends each of PHSA, UBC, SFU, their respective
Affiliates and their respective Boards of Governors, officers, employees, faculty, students, invitees, and agents (the “Indemnitees”) from and against any and all Third Party Claims arising out of the exercise by TScan of its rights
under this Agreement, including without limiting the foregoing, against any damages or losses, consequential or otherwise, arising from or out of the use, research, development, or commercialization of the Licensed Patents or anything made, used,
sold or otherwise disposed of under the license granted under this Agreement by TScan, its Affiliates or its Sublicensees, or their respective customers or end-users, including but not limited to any patent
infringement claim. TScan acknowledges and agrees that UBC and SFU are third party beneficiaries of TScan’s obligations under this Article 9, Schedule B and the other provisions of this Agreement that specifically refer to UBC or SFU.

  

	9.2	 Indemnification Procedure. TScan’s obligation to indemnify the Indemnities under Seciton 9.1. is
conditioned on (a) any Indemnitee seeking indemnification hereunder notifying TScan in writing reasonably promptly after receipt by it of written notice of any Third Party Claim in respect of which it intends to base a claim for indemnification
hereunder, (b) TScan having the right, upon providing notice to PHSA and, where the Indemnitee is not PHSA, such other Indemnitee of its intent within [***] days after receipt of the notice from the Indemnitee of any Third Party Claim, to
assume the defense and handling of such Third Party Claim, at TScan’s sole expense, and (c) TScan having control over selection of counsel reasonably acceptable to the Indemnitee in connection with conducting the defense and handling of
such Third Party Claim. TScan will defend or handle such defense in reasonable consultation with the Indemnitee, and will keep the Indemnitee reasonably apprised of the status of such Third Party Claim. The Indemnitee will reasonably cooperate with
TScan with respect to such Third Party Claim, at the request and expense of TScan. TScan will not settle such Third Party Claim without obtaining the Indemnitee’s prior written consent, which will not be unreasonably withheld, except no consent
is needed in the case of a settlement that does not admit liability on the part of any Indemnitee or otherwise impose on any Indemnitee any liability or obligations, and so long as the Indemnitees are unconditionally released from all liability in
such settlement. Without limiting the foregoing, each Indemnitee will be entitled to appoint separate counsel to assist such Indemnitee in the defense and handling of such Third Party Claim with its own counsel and at its own expense.

  

	9.3	 Limitation of Liability. The total, aggregate liability of PHSA, UBC, SFU and their Affiliates
considered together, whether under the express or implied terms of this Agreement, in tort (including negligence) or at common law, for any loss or damage suffered by TScan, its Affiliates or its Sublicensees, whether direct, indirect,
consequential, incidental or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by any Indemnitees, is limited to CAD$[***] except only that PHSA’s liability for a breach of PHSA’s
warranty in Section 8.2 (but not a breach of PHSA’s warranty under Section 8.1 or otherwise under this Agreement) shall be limited to the greater of $[***] or the amount actually paid by TScan to PHSA under this Agreement in the [***]
period prior to a Claim being made in writing by TScan to PHSA for breach of that warranty under Section 8.2. 

  
 - 15 - 

	9.4	 Damages Exclusions. TSCAN ACKNOWLEDGES AND AGREES THAT PHSA AND THEIR AFFILIATES WILL NOT BE LIABLE FOR
INDIRECT, CONSEQUENTIAL, INCIDENTAL, OR SPECIAL DAMAGES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. PHSA ACKNOWLEDGES AND AGREES THAT TSCAN, ITS AFFILIATES AND THEIR SUBLICENSEES WILL NOT BE LIABLE FOR INDIRECT, CONSEQUENTIAL, INCIDENTAL,
OR SPECIAL DAMAGES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THIS CLAUSE WILL NOT BE CONSTRUED TO LIMIT TSCAN’S INDEMNIFICATION OBLIGATIONS WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTIONS 9.1 AND 9.2.

  

	9.5	 Insurance. TScan will have and maintain such type and amounts of liability insurance covering its
activities and responsibilities under this Agreement as is normal and customary in TScan’s industry generally for similarly-situated entities. Upon PHSA’s written request from time to time, TScan will promptly furnish to PHSA a certificate
of insurance or other evidence of such insurance. Without limiting the generality of the foregoing, TScan will, at its own cost and expense, obtain and maintain in full force and effect during the Term (and, if any of the following policies of
insurance are written on a claims made basis, for a period of at least three (3) years thereafter), insurance with coverage and minimum policy limits set forth as follows: 

 

	 	(a)	 Commercial General Liability Insurance (including Public Liability Insurance) with a per-occurrence limit of not less than USD$[***]. 

  

	 	(b)	 Products and Completed Operations Liability Insurance with a
per-occurrence limit of not less than USD$[***]; provided, however, that TScan need not obtain or maintain such insurance prior to the initiation of the first Clinical Trial of any product that is covered
under a Licensed Patent. 

  

	 	(c)	 Not less than one (1) month before the start of (A) any Clinical Trials of a product referred to in
(b), or (B) the first use by TScan, its Affiliates or any of its Sublicensees of the Licensed Patents in exchange for valuable consideration, TScan will give notice to PHSA of the terms and amount of the product liability, Clinical Trials
public liability, and commercial general liability insurance which TScan, its Affiliates or any of its Sublicensees have placed. Without limiting the generality of the foregoing, neither TScan, its Affiliates nor any of its Sublicensees will start
any Clinical Trials, or sell or offer to sell any product referred to in (b) or use the Licensed Patents in exchange for valuable consideration, unless the insurance outlined above in reasonable amounts is in effect, with a reputable and
financially secure insurance carrier, and TScan has provided to PHSA an insurance certificate evidencing such insurance. The above policies of insurance described in this Section 9.5(c) will: 

 

	 	(i)	 include as additional insureds the following: PHSA, UBC, SFU, their respective Board of Governors, faculty,
officers, employees, students, invitees and agent; 

  
 - 16 - 

	 	(ii)	 provide coverage regarding all activities under this Agreement; 

 

	 	(iii)	 include a waiver of subrogation against PHSA, UBC and SFU, and a severability of interest and cross-liability
clauses; and 

  

	 	(iv)	 provide that the policies cannot be cancelled or materially altered except on at least [***]days’ prior
notice to PHSA, UBC and SFU. 

 ARTICLE 10 

TERM; TERMINATION 
  

	10.1	 Term. The term of this Agreement will continue in its entirety until the date of expiration of the last
Licensed Patent in the Territory, unless earlier terminated in accordance with the terms of this Agreement (the “Term”). 

  

	10.2	 Termination for Breach. 

 

	 	(a)	 Without limiting PHSA’s rights to seek damages or injunctive relief in connection with any breach by TScan
of this Agreement, PHSA may terminate this Agreement on written notice to TScan in the event: 

  

	 	(i)	 PHSA is entitled to terminate this Agreement pursuant to Section 7.2; 

 

	 	(ii)	 TScan fails to pay to PHSA, individually or in the aggregate, US $[***]or more owing pursuant to this Agreement
unless the payment of such amount is being disputed in good faith by TScan; or 

  

	 	(iii)	 TScan fails to comply with the material terms of this Agreement set forth in Articles 2 and 9 and, even if such
failure relates to any of such Articles, for which monetary damages is not an adequate remedy; 

 and TScan fails to cure
such failure after receiving two separate written notices from PHSA specifying such failure (with each such notice given by PHSA to TScan at least [***]days apart). 

Notwithstanding the foregoing, in the case of a notice given pursuant to this Section 10.2, and TScan in good faith notifies PHSA in
writing that it disputes whether such breach occurred, PHSA’s right to terminate shall be first referred for resolution pursuant to Article 11 and termination will be stayed pending the final resolution of such proceedings or mutual written
agreement of PHSA and TScan. If TScan fails to pay such Sublicensing Fee (plus interest calculated in accordance with Section 4.4(d) and any legal fees awarded pursuant to Article 11) or cure such breach, as applicable. within [***]days after
it is finally determined pursuant to Article 11 to be owing by TScan to PHSA, then PHSA may terminate this Agreement. 

  
 - 17 - 

	 	(b)	 Except as specifically provided in Section 10.2(a), neither Party shall have the right to terminate this
Agreement for breach by the other Party but the foregoing shall not relieve TScan from its obligations to terminate, or cause to be terminated, a Sublicense Agreement due to the material breach of the Sublicensee or preclude either party from
seeking an interim, interlocutory or final order for injunctive relief to prevent such material breach from continuing. Further, TScan’s termination of an applicable Sublicense Agreement shall be deemed to cure any breach hereof by TScan caused
by a breach of a Sublicensee, and PHSA shall not be entitled to terminate this Agreement as against TScan, any TScan Controlled Subsidiary or other Sublicensee pursuant to Section 10.2 but TScan shall remain liable to indemnify PHSA in respect
of such breach pursuant and subject to Section 9.1 and 9.2. 

  

	10.3	 Termination by TScan. TScan may terminate this Agreement at any time upon notice to PHSA provided that
no such termination under this Section 10.3 shall be effective until the later of (a) [***]months and one day after the Effective Date, and (b) TScan has made aggregate payments in the amount of $[***] to PHSA as otherwise would have been
required under Section 4.1 and Section 4.3 should this Agreement not have been terminated. For clarity, following the period referred to in Section 10.3(a), TScan may accelerate such payments for the purposes of early termination
pursuant to this Section 10.3. 

  

	10.4	 Effect of Termination. Upon expiration or termination of this Agreement: 

 

	 	(a)	 TScan will immediately pay to PHSA all amounts owing under this Agreement and not being disputed in good faith
by TScan; 

  

	 	(b)	 all licenses granted under this Agreement will immediately terminate and revert to PHSA, provided that all
Sublicense Agreements entered into with any Sublicensee (other than a TScan Controlled Subsidiary or TScan Affiliate) that have not previously been terminated shall survive provided that: 

 

	 	(i)	 TScan has paid to PHSA the Sublicensing Fee in respect of such Sublicense Agreement; 

 

	 	(ii)	 the Sublicensee is solvent; 

 

	 	(iii)	 Sublicensee or its Sublicensee Affiliates are in compliance in all material respects with the Sublicense
Agreement; and 

  

	 	(iv)	 such Sublicensee enters into an agreement with PHSA in substantially the same form as this Agreement to become
a direct licensee of PHSA, which Agreement does not require additional payment of Sublicensee to retain its existing rights, and except that in such agreement the equivalent of Section 9.3 of this Agreement shall automatically be amended to
delete the words “except only that PHSA’s liability for a breach of PHSA’s warranty in Section 8.2 (but not a breach of PHSA’s warranty under Section 8.1 or otherwise under this Agreement) shall be limited to the
greater of $[***]or the amount actually paid by TScan to PHSA under this Agreement in the [***]period prior to a Claim being made in writing by TScan to PHSA for breach of that warranty under Section 8.2” so that Section 9.3 of such
replacement license agreement shall read as follows: 

  
 - 18 - 

	 	“9.3 Limitation of Liability. The total, aggregate liability of PHSA, UBC, SFU and their Affiliates considered together, whether under the express or implied terms of this Agreement, in tort (including negligence)
or at common law, for any loss or damage suffered by TScan, its Affiliates or its Sublicensees, whether direct, indirect, consequential, incidental or special, or any other similar damage that may arise or does arise from any breaches of this
Agreement by any Indemnitees, is limited to CAD$[***].” 

  

	 	(c)	 each Receiving Party will deliver to the Disclosing Party or destroy the Disclosing Party’s Confidential
Information except that the Receiving Party may retain (i) one (1) copy of the Disclosing Party’s Confidential Information for legal archival purposes; and (ii) shadow or back-up copies which
may remain within the Receiving Party’s computer systems or its back-up or electronic archive systems until such time as such back-up copies are overwritten in
accordance with the Receiving Party’s reasonable document retention policies, and provided such back-up copies will not be accessed or used by anyone except as necessary and subject to the same terms and
conditions as those contained in this Agreement. Each Receiving Party will deliver to the Disclosing Party a certificate of an officer of the Receiving Party certifying its compliance with this Section 10.4(c). 

 

	10.5	 Survival. Any expiration or termination of this Agreement will not relieve either Party of any
obligation or liability accrued hereunder prior to such expiration or termination. In addition, Article 46, 9, Section 10.4, Section 10.5, Section 10.6, and Articles 11 to and including 13, and any right, obligation, or required
performance of the Parties which, by its express terms is intended to survive termination or expiration of this Agreement, will survive any such termination or expiration. 

 

	10.6	 Rights in Bankruptcy. PHSA hereby acknowledges and agrees, on behalf of itself and its Affiliates, that
TScan, as licensee of rights under this Agreement, may retain and fully exercise all its rights under any provision of Section 65.11 of the Bankruptcy and Insolvency Act of Canada (the “BIA”) and Section 32 of the
Companies’ Creditors Arrangement Act of Canada (the “CCAA”), and that TScan will retain its rights to use the Licensed Patents under Section 65.11(7) of the BIA and Section 32(6) of the CCAA in
any event. Without limiting the foregoing, TScan will have the benefit of any laws in force from time to time which provide for the protection of licensees’ rights generally in the event of an insolvency of PHSA. For the purposes of ensuring
that PHSA has the rights afforded to it pursuant to the rights and licenses granted by TScan to PHSA under this Agreement will apply, mutatis mutandis, to any proceedings, actions or motions brought in respect of TScan or its Affiliates under
the CCAA, BIA or similar provisions in the bankruptcy laws of other jurisdictions. 

  
 - 19 - 

 ARTICLE 11 

DISPUTE RESOLUTION/GOVERNING LAW 
  

	11.1	 Dispute Resolution. 

 

	 	(a)	 The Parties agree that in the event of a Dispute between PHSA and TScan arising out of or in connection with
this Agreement, or in respect of any legal relationship associated therewith or derived therefrom, the Parties will undertake good faith efforts to resolve any such Dispute, with the Dispute being referred at the request of either Party to a senior
representative of each Party. 

  

	 	(b)	 If after [***] days of the Dispute first being referred to the senior representatives the Parties are unable to
resolve such Dispute, either Party may refer the matter to arbitration pursuant to Section 11.2. 

  

	 	(c)	 Notwithstanding any term of this Article 11, a Party may apply to any court of competent jurisdiction for any
temporary injunctive or provisional relief necessary to protect the rights or property of that Party pending final resolution of the Dispute as contemplated by this Article 11. 

 

	11.2	 Arbitration. All Disputes will be referred to and finally resolved by arbitration by a single arbitrator
and administered by the Judicial Arbitration and Mediation Services, Inc. (“JAMS”) pursuant to its applicable Rules. The place of arbitration will be Vancouver, British Columbia, Canada. The arbitrator will have the power to award interim
or permanent injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved, and either Party may apply to a court of competent jurisdiction to enforce any injunctive relief granted by the arbitrator. Any final
award by the arbitrator may be entered by either Party in any court having appropriate jurisdiction for a judicial recognition of the decision and applicable orders of enforcement. The existence, content, and results of an arbitration will be the
Confidential Information of all Parties (i.e., each Party will be considered both the Disclosing Party and the Receiving with respect thereto), and, except to the extent necessary to confirm an award or as permitted by Article 6, neither a Party nor
the arbitrator may disclose any such information without the prior written consent of all Parties. In no event will an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or
claim would be barred by the applicable statute of limitations. 

  

	11.3	 Governing Law; Attornment. This Agreement will be governed by the laws of the Province of British
Columbia and the federal laws of Canada applicable therein. Subject to Sections 11.1 and 11.2, the Parties irrevocably submit to and accept generally and unconditionally the exclusive jurisdiction of the courts and appellate courts of British
Columbia with respect to any legal action or proceeding which may be brought at any time relating in any way to this Agreement. Each of the Parties irrevocably waives any objection it may now or in the future have to the venue of any such action or
proceeding, and any claim it may now or in the future have that any such action or proceeding has been brought in an inconvenient forum. 

  
 - 20 - 

 ARTICLE 12 

ASSIGNMENT 
  

	12.1	 OMITTED. 

  

	12.2	 Assignment. TScan shall not assign or transfer any of the rights granted to it under this Agreement
without the prior written consent of PHSA. For clarity, this Section 12.2 does not restrict TScan from sublicensing any of its rights under this Agreement in accordance with, and subject to the terms and conditions, set out in this Agreement.
Notwithstanding the foregoing, TScan may assign or transfer all of the rights granted to it under this Agreement without PHSA’s consent (a) to a TScan Controlled Subsidiary if TScan remains remain jointly and severally liable with such
TScan Controlled Subsidiary for their obligations under this Agreement; or (b) in connection with the sale of all or substantially all of its stock or business/assets to which this Agreement relates to such assignee. In the event that TScan
assigns this Agreement to an Affiliate that is not a TScan Controlled Subsidiary or to a Third Party that is not controlled by the same shareholders that controlled TScan prior to such assignment, such assignment will be deemed to be a Sublicense
Agreement entered into by TScan to a Third Party and conditional on payment by the assignee to PHSA of the Sublicensing Fee pursuant to Section 4.2. PHSA will have the right to assign its rights, duties and obligations under this Agreement
without the consent of TScan to a society which it has incorporated or which has purposes which are consistent with the objectives of PHSA or to a purchaser of all or substantially all of its business or assets related to the Licensed Patents.

 In the case of any such assignment as permitted by this Section 12.2: (A) the assigning Party must provide notice
of the assignment to the other Party; (B) the assignee must concurrently with the assignment agree in writing to assume all obligations and covenants of the assignor and to be bound by this Agreement and the assignee must provide an undertaking
to this effect to the other Party; and (C) in the event of an assignment of this Agreement by PHSA, any such assignment will include an assignment of all of such PHSA’s right, title and interest in the Licensed Patents. 

No assignment will release the assigning Party from any liability and obligations in respect of the assigned rights and obligations, except as
may be otherwise agreed in writing by the Parties at such time. Any attempt by any Party to assign any of the rights or obligations of this Agreement except as permitted by this Agreement is void. 

ARTICLE 13 

MISCELLANEOUS 
 13.1 Management
of Conflicts of Interest. 
  

	 	(a)	 TScan acknowledges that it is aware of PHSA’s, UBC’s and SFU’s respective policies on conflict
of interest, patents and licensing, and research, and that PHSA, UBC and SFU may amend these policies or introduce new policies from time to time. TScan agrees that: 

 

	 	(i)	 the facilities and research programs of TScan will be conducted independently of all PHSA, UBC or SFU
facilities, faculty, students or staff during the period of their employment with PHSA; and 

  
 - 21 - 

	 	(ii)	 no students, post-doctoral fellows or other PHSA, UBC or SFU staff will participate or be involved in
TScan’s research, projects or utilize TScan’s facilities. 

 The express terms of this Agreement, including the
rights and obligations of the Parties, will not be changed or altered as a result of any change in policies implemented during the Term. 
  

	13.2	 BC Cancer. Each Party will be responsible for compliance with this Agreement by any of its Affiliates.
BC Cancer, a part of PHSA, may carry out PHSA’s obligations under this Agreement. 

  

	13.3	 Waiver. The waiver by either Party of a breach or default of any provisions of this Agreement by the
other Party will not be construed as a waiver of any succeeding breach of the same or any other provision, nor will any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may
have hereunder operate as a waiver of any right, power or privilege of such Party. No waiver will be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified
other than by a written document signed by authorized representatives of each Party. 

  

	13.4	 Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties hereto
and will supersede all previous communications, representations and understandings, either oral or written, between the Parties relating to the subject matter hereof, and will not be subject to any change or modification except by the signing of a
written instrument by or on behalf of both Parties. There is no representation, warranty, collateral term or condition or collateral agreement affecting this Agreement, other than as expressed in writing in this Agreement. 

 

	13.5	 Notices. Any notice or other communication required or permitted to be made or given to either Party
hereto pursuant to this Agreement will be sufficiently made or given on the date of receipt if sent to such Party by: (i) overnight or other courier that provides documented proof of delivery; (ii) registered mail; or (iii) scanned
and converted into a portable document format file (i.e., pdf file), and sent as an attachment to an e-mail message, where, when such message is received, a read receipt
e-mail is received by the sender (and such read receipt e-mail is preserved by the Party sending the notice), provided further that a copy is promptly sent by an
internationally recognized overnight delivery service (receipt requested) (although the sending of the e-mail message will be when the notice is deemed to have been given), addressed to it as stated herein
below, or to such other address as it will designate by notice given to the other Party. 

  

	 	(b)	 In the case of PHSA: 

To Provincial Health Services Authority: 

BC Cancer Research Centre 
 675
West 10th Avenue 
 Vancouver, British Columbia, Canada 

V5Z1L3 
 Attention: Technology
Development Office 

  
 - 22 - 

	 	(c)	 In the case of TScan: 

TScan Therapeutics Inc. 
 830
Winter Street 
 Waltham, Massachusetts, U.S.A. 

02451 
 Attention: Shane Maltbie,
Vice President Finance 
 E-mail address: [***] 

 

	13.6	 Severability. If any part or parts of this Agreement will be held unenforceable for any reason, the
remainder of this Agreement will continue in full force and effect. If any provision of this Agreement is deemed invalid or unenforceable by any court of competent jurisdiction, and if limiting such provision would make the provision valid, then
such provision will be deemed to be construed as so limited. 

  

	13.7	 Export. Each Party agrees that it will not export or re-export
restricted commodities or the technical data of the other Party in any form without appropriate Canadian and foreign government licenses. 

  

	13.8	 Further Assurances. Each Party will execute and, if necessary, file with the appropriate governmental
entities, such documents, and cooperate with the other Party to take such further action, as the other Party will reasonably request, to carry out the purposes of this Agreement. 

 

	13.9	 Relationship of Parties. Nothing in this Agreement will be construed as constituting the Parties as
partners, joint venturers or legal entity of any type or as creating the relationships of employer/employee, franchisor/franchisee or principal/agent between the Parties. 

 

	13.10	 Force Majeure. The failure or delay of any Party to this Agreement to perform any obligation under this
Agreement solely by reason of acts of God, acts of civil or military authority, civil disturbance, war, strikes or other labour disputes or disturbances, fire, transportation contingencies, shortage of facilities, fuel, energy, labour or materials,
or laws, regulations, acts or orders of any Governmental Authority or official, other catastrophes, or any other circumstance beyond its reasonable control (“Force Majeure”) will be deemed not to be a breach of this Agreement so
long as the Party so prevented from complying with this Agreement has not contributed to such Force Majeure, has used reasonable efforts to avoid such Force Majeure or to ameliorate its effects, and continues to take all actions within its power to
comply as fully as possible with the terms of this Agreement. In the event of any such Force Majeure, performance of the obligations will be deferred until the Force Majeure ceases. This Section will not apply to excuse a failure to make any payment
when due. Regardless of any other provision of this Agreement, if one or more events of Force Majeure prevent PHSA, on the one hand, or TScan, on the other hand (in such capacity, the “Party Claiming Force Majeure”), from fully
performing their respective obligations hereunder for more than [***]days in the aggregate, then, the Party not claiming Force Majeure will be entitled, in their sole discretion, to terminate this Agreement without penalty, by providing notice
thereof to the Party Claiming Force Majeure. 

  
 - 23 - 

	13.11	 Headings. The headings of the several sections are inserted for convenience of reference only and are
not intended to be a part of or to affect the meaning or interpretation of this Agreement. Unless specified to the contrary, references to Articles, Sections or Schedules mean the particular Articles, Sections or Schedules to this Agreement and
references to this Agreement include all Schedules hereto. In the event of any conflict between the main body of this Agreement and any Schedule hereto, the main body of this Agreement will prevail. 

 

	13.12	 Interpretation. Unless the context of this Agreement otherwise requires, to the extent necessary so that
each clause will be given the most reasonable interpretation, the singular number will include the plural and vice versa, the verb will be construed as agreeing with the word so substituted, and words importing the masculine gender will include the
feminine and neuter genders. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words “include” or “including” will be construed as incorporating, also, “but not limited to” or
“without limitation;” (b) the word “day” or “year” means a calendar day or Calendar Year unless otherwise specified; (c) the word “notice” will mean notice in writing (whether or not specifically stated)
and will include notices, consents, approvals and other written communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement
as a whole and not merely to the particular provision in which such words appear; (e) the words “will” and “will” have interchangeable meanings for purposes of this Agreement; (f) the word “or” will have the
inclusive meaning commonly associated with “and/or”; (g) provisions that require that a Party or the Parties “agree,” “consent” or “approve” or the like will require that such agreement, consent or approval be
specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (h) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current
amendments thereto or any replacement law, rule or regulation thereof; and (i) neither Party or its Affiliates will be deemed to be acting “under authority of” the other Party. 

 

	13.13	 Counterparts. This Agreement may be executed in several counterparts, each of which will be deemed an
original, and all such counterparts together will constitute but one and the same instrument. Delivery of an executed signature page to this Agreement by any Party by electronic transmission will be as effective as delivery of an originally executed
copy of this Agreement by such Party. 

  

	13.14	 Enurement. Subject to the restrictions on transfer contained in this Agreement, this Agreement will
enure to the benefit of and be binding on the Parties and their respective successors and assigns. 

  

	13.15	 Applicable Laws. The Parties will comply fully at all time with all Applicable Laws in their performance
under this Agreement of the territory in which the Parties conduct business. 

  

	13.16	 No Third Party Beneficiary. Except for the Indemnitees, who will be third party beneficiaries of the of
those terms expressly stated to be applicable to them in this Agreement with the right to enforce those terms against the Parties, this Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including
any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, except as otherwise expressly provided for in this Agreement. 

  
 - 24 - 

	13.17	 Expenses. Each Party will pay its own costs, charges and expenses incurred in connection with the
negotiation, preparation and completion of this Agreement. 

  

	13.18	 Construction. The Parties hereto acknowledge and agree that: (a) each Party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the
interpretation of this Agreement; and (c) the terms and provisions of this Agreement will be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement. 

  

	13.19	 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive unless
explicitly stated to be so, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  

	13.20	 Compliance with Anti-Corruption Laws. Notwithstanding anything to the contrary in this Agreement, each
Party agrees that: 

  

	 	(a)	 it will not, in the performance of this Agreement, perform any actions that are prohibited by Anti-Corruption
Laws applicable to such Party; 

  

	 	(b)	 it will adhere to its own internal anti-corruption policies and will not, in the performance of this Agreement,
directly or indirectly, make any payment, or offer or transfer anything of value, or agree or promise to make any payment or offer or transfer anything of value, to a government official or government employee, to any political party or any
candidate for political office or to any other Third Party with the purpose of influencing decisions related to either Party or its business in a manner that would violate applicable Anti-Corruption Laws; and 

 

	 	(c)	 it will promptly provide notice to the other Party of any violations of Anti-Corruption Laws by such Party, its
Affiliates or sublicensees, or persons employed by or subcontractors used by such Party or its Affiliates or sublicensees in the performance of this Agreement of which it becomes aware.. 

 

	13.21	 Anti-Bribery Commitment. Without limiting the other obligations of the Parties set forth in this
Agreement, in connection with any activities of the Parties under this Agreement, the Parties confirm that they have not given, offered, promised, or authorized, and will not give, offer, promise, or authorize, any payment, benefit, or gift of money
or anything else of value, directly or through a Third Party, to: (i) any Public Official; (ii) any political party, party official or candidate for public or political office; (iii) any Person while knowing or having reason to know
that all or a portion of the value will be given, offered or promised, directly or indirectly, to anyone described in terms (i) or (ii) above; or (iv) any owner, director, employee, representative or agent of any actual or potential
customer of the Parties, for purposes of influencing any act or decision of such individual in his official capacity, inducing such individual to do or omit to do any act in violation of the individual’s duty, inducing the individual to use the
individual’s official influence with a 

  
 - 25 - 

	 	
government to affect or influence an act or decision of the government, or to secure any improper advantage in order to assist in obtaining or retaining business. In connection with any
activities or the Parties under this Agreement, the Parties will comply with all applicable anti-bribery laws of any jurisdiction, including any record keeping requirements of such laws, in the countries where such Party has their principal places
of business and where it conducts any activities under this Agreement.  

 (Signature page follows.) 

  
 - 26 - 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date. 

 

			
	PROVINCIAL HEALTH SERVICES AUTHORITY
		
	By:	 	  

		 	Name: [***]
		 	Title: [***]Cancer
		
	By:	 	  

		 	Name: [***]
		 	Title: [***]Office, Provincial Health Services Authority
	
	TSCAN THERAPEUTICS INC.
		
	By:	 	 /s/ Shane Maltbie

		 	Name: Shane Maltbie
		 	Title: Vice President, Finance

  
 - 27 - 

 SCHEDULE A 

LICENSED PATENTS 
  

	1.	 US patent No. [***] 

  

	2.	 US patent application No. [***] 

 

	3.	 Canadian patent application No. [***] 

 

	4.	 U.S. Provisional Patent Application No. [***] 

 

	5.	 PCT International Patent Application No. PCT/[***] 

 

	6.	 U.S. Utility Patent Application No. [***] 

 SCHEDULE B 

MANDATORY SUBLICENSING PROVISIONS 
 1. The
Sublicensee will acknowledge that nothing in the Sublicense Agreement grants to it any ownership in the sublicensed Licensed Patents except for the non-exclusive license to use such sublicensed Licensed
Patents in accordance with the Sublicense. 
 2. The Sublicensee, its Sublicensee Controlled Subsidiaries and their Sublicensees shall comply with all
Applicable Laws in connection with the exploitation of the Licensed Patents. 
 3. The Sublicensee will keep and use all of PHSA’s Confidential
Information in confidence and will materially conform with the obligations of confidentiality imposed upon TScan with respect to PHSA confidential information in this Agreement. 

4. Except as required under Applicable Laws or the rules of any Securities Regulators, the Sublicensee will agree not to use PHSA’s, UBC’s or
SFU’s name, trade-marks, service marks, logos, insignia, seal, or designs without the prior written consent of PHSA. 
 5. The Sublicensee will procure
and maintain insurance as provided for in this Agreement. 
 6. The Sublicensee will acknowledge and agree that PHSA, UBC and SFU make no representations,
conditions or warranties, either express or implied, to the Sublicensee with respect to the Licensed Patents. Without limiting the generality of the foregoing, the Sublicensee will acknowledge that PHSA specifically disclaims any express or implied
warranty, condition or representation: 
 (a) that anything made, used, sold or otherwise disposed of under the Sublicense Agreement granted
to the Sublicensee correspond with a particular description, are of merchantable quality, are fit for a particular purpose or are durable for a reasonable period of time; and 

(b) as to title to the Licensed Patents, or that anything made, used, sold or otherwise disposed of under the Sublicense Agreement granted to
the Sublicensee will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property rights of any third parties, including any patents, copyrights, trade-marks, industrial design or other intellectual property
rights owned, in whole or in part, by PHSA, or licensed by PHSA to any third parties; 
 (c) that the Sublicensee has, or will have, the
freedom to operate or practice the Licensed Patents. 
 7. The Sublicensee will acknowledge and agree that PHSA, UBC and SFU will not be liable for any loss,
whether direct, consequential, incidental or special, which the Sublicensee or any other third parties suffer, arising from any defect, error or fault of the Licensed Patents or anything made, used, sold or otherwise disposed of under the Sublicense
Agreement granted to the Sublicensee, or their failure to perform, even if PHSA, UBC or SFU is aware of the possibility of the defect, error, fault or failure. The Sublicensee will also acknowledge that it has been advised to undertake its own due
diligence regarding the Licensed Patents, and that PHSA is under no obligation to bring, prosecute or defend actions or suits against third parties for infringement of patents, copyrights, trademarks, industrial designs or other intellectual
property or contractual rights in relation to the Licensed Patents. 

 8. The Sublicensee will indemnify, hold harmless and defend PHSA, UBC, SFU and their respective Boards of
Governors, Board of Directors, officers, employees, faculty, students, invitees and agents against any and all claims (including all associated legal fees and disbursements actually incurred) in a manner consistent with the terms of TScan’s
indemnification obligations under this Agreement. 
 9. The Sublicensee will agree to limit its claims against PHSA, UBC and SFU, whether under the express
or implied terms of the Sublicense Agreement or this Agreement, in tort (including negligence) or at common law, for any loss or damage suffered by the Sublicensee, whether direct, indirect or special, or any other similar damage that may arise or
does arise from any actions or inactions, defaults or breaches by PHSA, UBC or SFU or their respective Board of Governors, Board of Directors, officers, employees, faculty, students or agents, to the amount of CDN. $[***]. 

10. The Sublicensee will also acknowledge and agree that PHSA, UBC and SFU will not be liable for consequential or incidental damages, including any
consequential or incidental damages arising from any breach or breaches of the Sublicense Agreement or this Agreement. 
 11. The Sublicense Agreement will
include termination provisions in respect of the Sublicensee’s rights in respect of the Licensed Patents or obligations to be imposed on the Sublicensee in accordance with this Agreement as apply to its obligations in respect of the TScan
Technology License or other similar obligations under the Sublicense Agreement to TScan, a TScan Controlled Subsidiary or, in the case of a sub-sublicense, a Sublicensee and will include a provision providing
that the Sublicense Agreement as it relates to the Licensed Patents will terminate: 
 (a) upon termination of this Agreement between PHSA
and TScan unless the particular Sublicensee enters into a direct license agreement with PHSA on, and subject to the terms set out in, Section 10.4(b); 

(b) if the Sublicensee is in material breach of its obligations under the Sublicense Agreement as it relates to the Licensed Patents or
obligations required pursuant to Section 2.3 and Schedule B of this Agreement, and such breach is not cured within the cure period set out in the Sublicense Agreement; 

(c) If the Sublicensee or any of its Affiliates commences a Patent Challenge (as defined in the Agreement), and does not withdraw such Patent
Challenge within [***]days after PHSA’s notice to Sublicensee thereof. For clarity, in the case of a Sublicensee, the references in Section 7.2 to TScan and a TScan Affiliate or TScan Controlled Subsidiary shall be deemed to be to the
Sublicensee and its Affiliates. 

  
 B - 2 

 SCHEDULE C 

TSCAN CONTROLLED SUBSIDIARIES 
 As of the
date of this Agreement, the following are TScan Controlled Subsidiaries: 
 TScan Securities Corporation 

 

  
 B - 3 

 SCHEDULE D 

REQUIRED REPORTING ON SUBLICENSE AGREEMENTS 
  

	1.	 Date Sublicense Agreement was entered into with the particular Sublicensee. 

 

	2.	 Full legal name of Sublicensee. 

 

	3.	 Description of other TScan Patents or Know-How included licensed
concurrently to such Sublicensee sufficient for PHSA to confirm compliance with Section 2.3 and Schedule B. 

  

	4.	 Excerpt of the signed Sublicense Agreement sufficient to confirm the above information and compliance with
Schedule B (and for greater certainty, excluding any financial terms or terms not strictly necessary to confirm the foregoing). 

  
 B - 4EX-10.10

 Exhibit 10.10 

AMENDED AND RESTATED 

ROYALTY AGREEMENT 
 THIS
AMENDED AND RESTATED ROYALTY AGREEMENT (the “Agreement”) is entered into as of June 12, 2018 (the “Effective Date”), by and between T-Scan
Therapeutics, Inc., a Delaware corporation, having offices at Prudential Tower, 800 Boylston Street, Suite 1555, c/o Longwood Fund, Boston, MA 02199 (the “Company”) and Christoph Westphal, an individual with an address of
(the “Founder”). The Company and the Founder are individually referred to herein as a “Party” and are collectively referred to herein as the “Parties.” 

WHEREAS, the Parties previously entered into that certain Royalty Agreement dated as of April 24, 2018 (the “Prior Royalty
Agreement”), and, in connection with a potential financing of the Company, the Parties wish to amend and restate the Prior Royalty Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the foregoing premises and the covenants and promises set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 
  

	1.	 DEFINITIONS 

1.1 “Affiliate” with respect to any entity, means any company or entity controlled by,
controlling, or under common control with such referenced entity and shall include any company more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by such referenced entity, and any
company which owns or controls, directly or indirectly, more than fifty percent (50%) of the voting stock of such entity. 

1.2 “Control” means, with respect to any Patents, that the Company (a) owns or
(b) has a license to such Patents and, in each case, has the ability to grant access, a license, or a sublicense (as applicable) to the foregoing without violating the terms of any then-existing agreement or other arrangement with any Third
Party. 
 1.3 “Cover,” “Covering” or “Covered”
means, with respect to a product, that, in the absence of ownership of, or a license under, the Subject Patents, the Exploitation of such product would infringe a Valid Claim of a Subject Patent.  

1.4 “Exploit” means to research, develop, make, have made, use, offer for sale, sell, import,
export or otherwise exploit, or transfer possession of or title in, a product. Cognates of the word “Exploit” shall have correlative meanings. 

1.5 “First Commercial Sale” means, with respect to any Royalty-Bearing Product in any country,
the first sale for end use or consumption of such Royalty-Bearing Product in such country after marketing approval has been granted in such country. 

  
 1 

 1.6 “Licensee” means any person or entity
that directly or indirectly licenses or sublicenses Subject Patents from the Company or any Affiliate of the Company to develop, manufacture, or sell products used in the treatment of any disease or disorder. For the avoidance of doubt, any person
or entity that receives a sublicense to any such intellectual property from any other person or entity which licensed or sublicensed them from Company or any of its Affiliates will be considered a “Licensee” for purposes of this Agreement.

 1.7 “Net Sales” means, with respect to any Royalty-Bearing Product, the gross sales price
of such Royalty-Bearing Product sold by the Company, its Affiliates or Licensee(s) (the “Selling Party”) to Third Parties, less: 
  

	 	(a)	 non-recoverable sales taxes, excise taxes (including annual fees due
under Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48)), use taxes, value-added taxes and duties paid by the Selling Party in relation to
Royalty-Bearing Product(s) and any other equivalent governmental charges imposed upon the importation, use or sale of Royalty-Bearing Product(s) (excluding taxes when assessed on income derived from sales); 

 

	 	(b)	 credits and allowances (actually allowed or paid) for defective or returned Royalty-Bearing Product(s),
including allowances for spoiled, damaged, out-dated, rejected, returned, withdrawn or recalled Royalty-Bearing Product(s), and the actual amount of any write-offs for bad debt (capped at 2% of Net Sales for
the applicable period) (provided, however, that any amount subsequently recovered will be treated as Net Sales); 

  

	 	(c)	 governmental and other rebates, refunds, and chargebacks (or equivalents thereof) granted to managed health
care organizations, pharmacy benefit managers (or equivalents thereof), federal, state, provincial, local and other governments, their agencies and purchasers and reimbursers or to trade customers, in each case with respect to such Royalty-Bearing
Product; 

  

	 	(d)	 reasonable fees paid to wholesalers, distributors, selling agents (excluding any sales representatives of a
Selling Party), group purchasing organizations, Third Party payors, other contractees and managed care entities, in each case with respect to such Royalty-Bearing Product; 

 

	 	(e)	 reasonable transportation charges relating to Royalty-Bearing Product(s), including handling charges and
insurance premiums relating thereto to the extent included as a separate entry on the invoice for such product (provided, however, that the total of all items in subsection 1.7(e) shall be capped at 2% of the gross sales price for the relevant
period); 

  

	 	(f)	 retroactive price reductions actually granted to the Third Party applicable to sales of such Royalty-Bearing
Product; and 

  
 2 

	 	(g)	 trade, cash, prompt payment and/or quantity discounts, actually allowed and taken directly by the Third Party,
and mandated discounts. 

 Net Sales will be determined from books and records maintained in accordance with GAAP,
consistently applied throughout the organization and across all products of the entity whose sales of Royalty-Bearing Products are giving rise to Net Sales. 

Where a Royalty-Bearing Product is sold in combination with other pharmaceutical products, diagnostic products, or active ingredients
(collectively, “Combination Components”) the Net Sales applicable to such transaction shall be calculated by multiplying the total Net Sales of such combined product by the fraction A/(A+B), where A is the actual price of the
Royalty-Bearing Product in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately, and B is the sum of the actual prices of all Combination Components with which the Royalty-Bearing Product is
combined, in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately. If A or B cannot be determined because values for the Royalty-Bearing Product or Combination Components with which the
Royalty-Bearing Product is combined are not available separately in a particular country, then the Company and the Founder shall discuss an appropriate allocation for the fair market value of the Royalty-Bearing Product and Combination Components
with which the Royalty-Bearing Product is combined to mutually determine Net Sales for the relevant transactions based on an equitable method of determining the same that takes into account variations in potency, the relative contribution of each
therapeutically active ingredient or other component, and relative value to the end user of each therapeutically active ingredient or other component. 

Sales of Royalty-Bearing Product(s) between or among the Company and its Affiliates or Licensees shall be excluded from the computation of Net
Sales and no payments shall be payable on such sales except where such Affiliates or Licensees are end users. 
 1.8
“Patents” means (a) all national, regional and international patent applications, including provisional patent applications; (b) all patent applications filed either from the patent applications which are the
subject of (a) or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted
provisionals, and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing patent applications in (a) and (b), including author certificates, inventor certificates, utility
models, petty patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues,
re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications in (a), (b) and (c); and (e) any similar rights, including
so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents. 

  
 3 

 1.9 “Royalty-Bearing Product”
means any and all products of the Company designed for use in the treatment of any disease or disorder that are Covered by a Valid Claim of a Subject Patent. 

1.10 “Royalty Term” means, on a
country-by-country and Royalty-Bearing Product-by-Royalty-Bearing Product basis, the
period beginning on the First Commercial Sale of the first Royalty-Bearing Product and ending on the later of (a) the date on which the Exploitation of a Royalty-Bearing Product is no longer Covered by a Valid Claim of a Subject Patent in such
country, or (b) the fifteenth (15th) anniversary of the First Commercial Sale of the first Royalty-Bearing Product in such country. 

1.11 “Subject Patent” means any Patent Controlled by the Company as of the last date the Founder
was either employed by the Company or provided services to the company as a director or as a consultant under a written agreement between the Company and the Founder. 

1.12 “Third Party” means any person or entity other than the Company, the Company’s
Affiliates or the Founder. 
 1.13 “Valid Claim” means a claim of a pending patent application
or issued patent, which claim has not lapsed, been cancelled, become abandoned, declared invalid by an unreversable and unappealable decision or judgment of a court of competent jurisdiction, and which claim has not been admitted to be invalid or
unenforceable through reissue or disclaimer; provided, however, that if a claim of a pending patent application within the Subject Patents shall not have issued within seven (7) years after the earliest filing date from which such claim
takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent issues with such claim (from and after which time the same would be deemed a Valid Claim). 

 

	2.	 ROYALTY 

2.1 Royalty. Within forty-five (45) days after the end of each calendar quarter during the applicable
Royalty Term, the Company shall pay to the Founder a royalty equal to one percent (1%) of Net Sales of Royalty-Bearing Products during such calendar quarter. 

2.2 Reports. Royalty payments and reports for the sale of Royalty-Bearing Products shall be calculated and
reported for each calendar quarter. Each payment of royalties shall be accompanied by a report of sales of Royalty-Bearing Products in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, without
limitation, the number of Royalty-Bearing Products sold, the gross sales of Royalty-Bearing Products, the deductions applied, the royalties payable and the method used to calculate the royalty. 

  
 4 

 2.3 Manner and Place of Payment. All payments hereunder shall
be payable in U.S. dollars. All payments owed under this Agreement shall be made by wire transfer to a bank and account designated in writing by the Founder. 

2.4 Income Tax Withholding. The Founder will pay any and all taxes levied on account of any payments made to him
under this Agreement. If any taxes are required to be withheld by the Company, the Company will (a) deduct such taxes from the payment made to the Founder, (b) timely pay the taxes to the proper taxing authority, and (c) send proof of
payment to the Founder and certify its receipt by the taxing authority within 30 days following such payment. 
 2.5
Audits. The Company shall keep (and shall cause its Affiliates and Licensees to keep) complete and accurate records pertaining to the sale or other disposition of Royalty-Bearing Products generated in the then current calendar year, and
during the preceding three (3) calendar years, in sufficient detail to permit the Founder to confirm the accuracy of all royalty payments due hereunder. The Founder shall have the right to cause an independent, certified public accountant
reasonably acceptable to the Company to audit any such records in the Company’s or its Affiliate’s possession to confirm sales and royalties for a period covering not more than the preceding three (3) years. Such audits may be
exercised during normal business hours upon reasonable prior written notice to the Company. Prompt adjustments shall be made by the Parties to reflect the results of such audit. The Founder shall bear the full cost of such audit unless such audit
discloses an underpayment by the Company of more than 10% of the amount of royalties due under this Agreement during the audited period, in which case, the Company shall bear the full cost of such audit and shall promptly remit to the Founder the
amount of any underpayment. The Founder may only exercise his audit rights under this Section 2.5 once in any twelve (12) month period. 

2.6 Licensees. Any license or sublicense granted by the Company will, to the extent related to Royalty-Bearing
Products, be consistent with the terms and conditions of this Agreement, and Company shall include in any licenses or sublicenses sufficient provisions to enable it to comply with the royalty provisions contained in this Agreement, including without
limitation, audit provisions substantially similar to those set forth in Section 2.5. As requested by the Founder, the Company shall enforce the provisions of its licenses and sublicenses applicable to the payment of royalties hereunder,
including conducting audits of Licensee records pertaining to the sale of Royalty-Bearing Products. Company shall remain primarily responsible for any failures by its Licensees to comply with the applicable terms of this Agreement, and of the terms
of license and sublicense agreements that enable compliance with the terms of this Agreement. 

  
 5 

	3.	 REPRESENTATIONS AND WARRANTIES 

3.1 Mutual Representations and Warranties. Each Party represents and warrants to the other that: (a) it has
full power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and (c) this Agreement is legally
binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any
court, governmental body or administrative or other agency having jurisdiction over it. 
 3.2 Disclaimer of
Warranties. Except as expressly set forth in this Agreement, NO PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF TITLE,
NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
  

	4.	 LIMITATION OF LIABILITY 

EXCEPT FOR PAYMENTS UNDER SECTION 2.1, NO PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTIES ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR
PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT. 
  

	5.	 TERM 

The term of this Agreement shall commence as of the Effective Date and shall continue until expiration of the last applicable Royalty Term.

  

	6.	 CONFIDENTIALITY 

The Founder will treat the royalty reports and any other confidential or proprietary information of the Company disclosed to the Founder
hereunder, as confidential information of the Company, will only use such information for the purposes of this Agreement, will protect it from unauthorized use, access, or disclosure in the same manner as the Founder protects its own confidential or
proprietary information of a similar nature and with no less than reasonable care, will disclose it only to the employees or agents of the Founder who have a need to know such information, if any, for purposes of this Agreement and who are under a
duty of confidentiality no less restrictive than the Founder’s duties hereunder, and will return to the Company or destroy all such information after expiration or termination of this Agreement. The Founder will be allowed to disclose
confidential information of the Company to the extent that such disclosure is (a) approved in writing by the Company or (b) required by law or by the order or a court of similar judicial or administrative body, provided that the Founder
notifies the Company of such required disclosure promptly and in writing and cooperates with the Company, at the Company’s request and expense, in any lawful action to contest or limit the scope of such required disclosure. 

  
 6 

	7.	 MISCELLANEOUS 

7.1 Assignment. Either Party may assign this Agreement and his/its rights and obligations hereunder to a Third
Party upon prior written notice to the other Party. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. As a condition to the
effectiveness of any assignment hereunder, any successor or assignee of rights or obligations permitted hereunder shall, prior to the effectiveness of such assignment, expressly assume in a writing provided to the other Party hereto the obligation
to perform the assigning Party’s obligations hereunder. For the avoidance of doubt, the Company may not sell, assign, convey, lease or otherwise transfer any Subject Patent to any Third Party unless such Third Party agrees to be bound by the
terms of this Agreement as if it were the Company hereunder. Any assignment not in accordance with this Agreement shall be void. 

7.2 Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws
of the Commonwealth of Massachusetts, without regard to its choice of law provisions. 
 7.3 Waiver. Except as
specifically provided for herein, the waiver from time to time by a Party of any right or failure to exercise any remedy shall not operate or be construed as a continuing waiver of the same right or remedy or of any other of such Party’s rights
or remedies provided under this Agreement. No waiver shall be valid or effective unless made in a writing referencing this Agreement and signed by the Party granting the waiver. 

7.4 Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable,
(a) the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby to the maximum extent possible and (b) in lieu of such invalid, illegal or unenforceable provision, there will
be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible to effectuate the intents and purposes of such provision. 

7.5 Notices. All notices and other communications provided for hereunder shall be in writing and shall be mailed
by first-class, registered or certified mail, postage paid, or delivered personally, by overnight delivery service or by facsimile, with confirmation of receipt, addressed to the address set forth for such Party in the introduction hereto. Either
Party may by like notice specify or change an address to which notices and communications shall thereafter be sent. Notices sent by facsimile shall be effective upon confirmation of receipt, notices sent by mail or overnight delivery service shall
be effective upon receipt, and notices given personally shall be effective when delivered. 

  
 7 

 7.6 Entire Agreement; Amendment. This Agreement sets forth all
of the agreements and understandings between the Parties hereto with respect to the subject matter hereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof (including
the Prior Royalty Agreement). There are no agreements or understandings with respect to the subject matter hereof, either oral or written, between the Parties other than as set forth herein. Except as expressly set forth in this Agreement, no
subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the Company and the Founder. 

7.7 Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or
labels to assist in locating and reading the several Articles hereof. 
 7.8 Counterparts. This Agreement may
be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. An executed signature page of this Agreement delivered by facsimile transmission, including
signatures in a fixed electronic format such as a PDF, will be as effective as an original executed signature page. 
 [Signature page
follows] 

  
 8 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set
forth above. 
  

			
	COMPANY:
		
	By:	 	/s/ Christoph Westphal

			
	Name:	 	Christoph Westphal
		
	Title:	 	Chief Executive Officer

  

	
	FOUNDER:
	
	/s/ Christoph Westphal
	Christoph Westphal

 SIGNATURE PAGE TO AMENDED &
RESTATED ROYALTY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]